Washington, D.C. 20549




Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )



Filed by the Registrant  ☒

Filed by a party other than the Registrant  ☐

Check the appropriate box:


Preliminary Proxy Statement


Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))


Definitive Proxy Statement


Definitive Additional Materials


Soliciting Material under §240.14a-12


(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):


No fee required


Fee paid previously with preliminary materials


Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11





P.O. BOX 8016, CARY, NC 27512-9903 Aligos Therapeutics, Inc. Important Notice Regarding the Availability of Proxy Materials Stockholders Meeting to be held on July 20, 2023 For Stockholders of record as of May 23, 2023 This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. To view the proxy materials, and to obtain directions to attend the meeting, go to: To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. For a convenient way to view proxy materials and VOTE go to Have the 12 digit control number located in the shaded box above available when you access the website and follow the instructions. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before July 10, 2023. To order paper materials, use one of the following methods. * E-MAIL * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above. Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K Meeting Type: Annual Meeting of Stockholders Date: Time: Place: INTERNET Aligos Therapeutics, Inc. Thursday, July 20, 2023 8:00 AM, Pacific Time Annual Meeting to be held live via the internet - Please visit for more details. SEE REVERSE FOR FULL AGENDA TELEPHONE (866) 648-8133


Aligos Therapeutics, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1 AND 2 PROPOSAL 1. The election of three Class II directors to hold office until our 2026 annual meeting of stockholders. 1.01 Jack B. Nielsen 1.02 Bridget Martell, M.A., M.D. 1.03 Carole Nuechterlein, J.D. 2. To ratify the appointment, by the Audit Committee of the Company’s Board of Directors, of Ernst &Young LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. 3. The transaction of such other business as may properly come before the meeting.